Santen Pharmaceutical Co Ltd
SZD
Company Profile
Business description
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.
Contact
Grand Front Osaka Tower A
4-20 Ofuka-cho, Kita-ku
Osaka530-8552
JPNT: +81 663217000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
3,849
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,094.90 | 27.60 | -0.30% |
| CAC 40 | 7,797.20 | 21.02 | -0.27% |
| DAX 40 | 23,301.42 | 27.82 | -0.12% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,217.61 | 21.95 | 0.24% |
| HKSE | 26,908.39 | 469.88 | 1.78% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
| NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
| SSE Composite Index | 3,876.34 | 14.48 | 0.37% |